Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ReShape Lifesciences Inc
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
November 14, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
November 12, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
November 12, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes
November 11, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
September 19, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
August 14, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
August 13, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
July 09, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
May 15, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
May 14, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
April 01, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
March 28, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
March 04, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
February 22, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
January 24, 2024
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
December 20, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
December 12, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
November 21, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
November 08, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
November 06, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
September 29, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
September 22, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
September 21, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
September 19, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
September 14, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update
August 07, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update
August 03, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
June 29, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
June 28, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
June 26, 2023
From
ReShape Lifesciences Inc
Via
GlobeNewswire
Tickers
RSLS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.